World news and discussion on TalkFuse.
AstraZeneca boss urges western drugmakers to move at ‘Chinese speed’
AstraZeneca's chief executive, Pascal Soriot, has warned that western pharmaceutical companies must adopt "Chinese speed" in drug development or risk being overtaken by increasingly innovative Chinese rivals, much as European and American carmakers lost ground to Chinese electric vehicle manufacturers. Speaking as the FTSE 100 firm reported its half-year results, Soriot said AstraZeneca was closely watching and collaborating with China's fast-growing pharmaceutical sector, while urging the wider western industry to accelerate innovation to avoid falling behind.
AstraZeneca reported revenues of £30.7bn for the first half of 2026, up 6% year-on-year at constant exchange rates, and said it remained confident of hitting its 2030 target of $80bn (£60bn) in annual sales, up from $59bn last year. This is despite the recent clinical trial failure of its heart disease drug Wainua, which Soriot described as an inevitable part of drug development. He also dismissed fears that AI would cut jobs in the sector, arguing it would instead boost productivity, and said the company would seek clarity from the new health secretary, Andy Burnham, over a US-brokered deal that could raise NHS drug costs by billions of pounds.
In short
- AstraZeneca boss says drugmakers must innovate faster to rival China
- Firm reports £30.7bn half-year revenue, confident of 2030 targets
- Soriot to seek clarity from new health secretary on costly US drug deal
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Western pharmaceutical companies can accelerate drug development through improved management, technology investment, and smart regulatory modernisation, allowing life-saving treatments to reach patients faster. The automotive sector's loss to Chinese competitors demonstrates the risks of complacency; companies that balance development speed with rigorous safety standards can compete globally and deliver genuine patient benefit.
The case against
Pharmaceutical development timelines exist because human health is at stake—the consequences of rushing safety testing are fundamentally different from automotive sector competition. The pressure to match "Chinese speed" risks incentivising regulatory corners to be cut; robust Western regulatory standards protect patients precisely by refusing to sacrifice evidence of safety and efficacy for faster timelines.
Explained simply
Western pharmaceutical companies are concerned about falling behind Chinese competitors who are developing new drugs faster. This trend mirrors what has happened in other industries, such as car manufacturing, where rapid innovation by Chinese firms has allowed them to gain significant market share against established European and American companies.
AstraZeneca, a major British pharmaceutical firm, has warned that the western drug industry needs to work faster if it wants to maintain its competitive advantage. The company's chief executive has specifically urged other western pharmaceutical companies to match what he calls "Chinese speed" in getting new drugs to market.
The issue matters because the speed at which pharmaceutical companies develop new drugs affects which companies dominate the global market and which new treatments reach patients worldwide. How quickly western firms can increase their pace may determine whether they retain their industry leadership or whether Chinese competitors capture an increasingly large share of the multibillion-pound global pharmaceutical market.
Americas Business Companies Europe Health Markets Medicine World